Pharmaceutical Industry Residency Program

Pharmaceutical Industry Residency Program (PIRP)

The Pharmaceutical Industry Residency Program, formerly named the Industrial Pharmacy Residency Program, is administered by the Leslie Dan Faculty of Pharmacy, University of Toronto, in cooperation with participating Pharmaceutical Companies as listed below. These one or two year specialty residencies develop critical knowledge and skills and provide experience within the stated functional area. This is a national educational residency program for graduates from a recognized Pharmacy degree program; it is not an application for a position with a pharmaceutical company.
 

Certification

Over the last few years, many residents and company supervisors have communicated a desire to formally certify the program and we are excited to announce that we have successfully achieved program certification through the Leslie Dan Faculty of Pharmacy, University of Toronto.

Current residents are eligible for the certificate provided they complete the requirements outlined in the terms of reference.

The Leslie Dan Faculty of Pharmacy will continue to support PIRP’s ability to provide high, quality, experiential learning through:

• Skills and educational webinars and exposure to pharmaceutical industry experts
• Resume and interview skills workshops
• Opportunity to network with PIRP residents and pharmaceutical industry professionals
• Participation in a new mentoring program with a PIRP graduate
• Collaboration with and guidance from University of Toronto faculty liaisons
• Coordination to address issues and ensure program requirements are met
   

PIRP Fees 

To help fund this program, starting in the 2027–28 cycle the program fees are as follows: 
Pharmaceutical company fees based on the number of residency positions offered: 

Applicant and resident non-refundable fees: 

• $250 at application (Due September) 
• $2250 once successfully matched with a company (Due August) 
• $2500 payable three months after residency employment starts (Due November) 
  
  

Applications Process

Applications for the 2027–2028 program: Open on Tuesday, September 1, 2026 at 5:00 PM ET | Close on October 1, 2026 at 5:00 PM ET.

Applications are now invited for Residencies starting Summer 2027. To apply:   

If you are a current U of T student (PharmD and PFP students who are graduating in Summer next year): Please click here where you will login with your UTORID to access the application form and process.  

If you are a graduated U of T student or a non U of T student: Please click here for a login. (This may take 3-5 business days so please do as soon as possible). Once your account has been activated, you can login here. Please note that you will not receive an email confirmation once the account has been created and will have to manually check by logging in.  

In the interim, you may prepare to upload the following as part of the application:  

1. Applicant Contact Information  

2. University Transcripts from Pharmacy program (in PDF format; unofficial copy accepted – verification may be required)  

3. Resume or CV  

4. Reference form (listing contact information of two referees) (click here)  

Once you have access to CLNx (the application system), please use this guideline to navigate the application process on CLNx.

For questions, please contact: pharm.residency@utoronto.ca. 
 

Key Dates for 2027-28 Residency Application Cycle 

2027-2028 Residency Program Participating Companies & Specialties 

1. Abbvie: Market Access, Immunology and Oncology 
2. Amgen: Medical Information and Medical Affairs | Value, Market Access & Policy
3. Alexion AstraZeneca: Global Medical Information, Neurology
4. AstraZeneca: Global Clinical Development, Late Oncology
5. Bayer: Medical Affairs, Oncology | Market Access
6. BioGen: Market Access, Rare Disease
7. Boehringer Ingelheim: Medical Affairs, Oncology | Medical Affairs, CRM | Medical Affairs, Inflammation  
8. Eisai: Medical Affairs, Oncology and Neurology 
9. Gilead: Medical Affairs, Virology and Oncology
10. Lilly: Medical Affairs, Medical Information | Medical Affairs, Cardiometabolic Health | Market Access, Pricing and Reimbursement 
11. Medison: Medical Affairs, Oncology and Rare Disease
12. Merck: Medical Information and Medical Review
13. Novo Nordisk: Medical Affairs, Cardiometabolic | Medical Affairs, Cardiorenal
14. Otsuka: Medical Affairs and Business Development
15. Sanofi: Medical Affairs, Medical Education & Operations | Medical Affairs, Oncology | Medical Affairs, Rare Diseases & Rare Blook Disorders | Medical Affairs, Immunology | Medical Affairs, Market Access | Medical Affairs, Vaccines | Medical Affairs, General Medicine
16. Takeda: Medical Affairs, Oncology

Download the PIRP Table of Positions 2027-28 below for more information